The Dr. GPCR community is gathering in Boston on April 29th for an informal evening of real conversation — no presentations, no agenda, just GPCR scientists in one room. Co-hosted with NIS, EuroscreenFast, and Montana Molecular. Space is limited to 50 scientists.

The gap between pharmacological screening and clinical translation has a structural explanation. Generic cell systems (usually) generate clean data — but they don't reflect the tissue environment, disease context, or signaling complexity that determines whether a compound actually works. This week's session examines what changes when you close that gap. Terry Hébert joins the Dr. GPCR community live on April 16 — one of 12+ Masterclasses planned for 2026, all included in Prem

Bryan Roth joins the Dr. GPCR community live this week to examine what standard models don't account for — what happens when GPCR selectivity is encoded at the receptor–transducer interface rather than the receptor alone. This is one of 12+ live Masterclasses planned for 2026, all included in Premium. Also this week: Terry Hébert previews his April 16 session on iPSC-derived models, and a new podcast episode with Joseph Kim on GPCR structural biology and drug discovery.

GPCR internalization does not end signaling — it redirects it. This article explores the assays, beta-arrestin gating mechanisms, and recycling-versus-degradation frameworks that determine receptor fate inside the cell.

Biased signaling is often interpreted through receptor conformations, yet selectivity can also emerge from the stabilization of receptor–transducer complexes. System-dependent variability adds a further layer: signaling profiles shift when biological context changes. This week’s sessions examine both.

Allosteric binding data interpretation challenges traditional assumptions about displacement, affinity, and receptor behavior. This analysis explores how receptor state redistribution, cooperativity, and system context reshape experimental meaning. The result is a more precise framework for interpreting complex pharmacological data.

Classic models explain biased GPCR signaling through ligands that stabilize distinct receptor conformations and thereby favor selective transducer interactions. This remains a powerful framework, but the examples highlighted this week point to an additional route: intracellular modulators that bind at receptor–transducer interfaces, alongside experimental systems that place GPCR signaling in more physiological cellular contexts.

Boston, MA and Irvine, CA — [March 18, 2026]  — Dr. GPCR, a nonprofit organization serving the global G protein-coupled receptor (GPCR) research community through education, curated scientific content, and community engagement, today announced a strategic media partnership with GeneTex, a multinational antibody manufacturer with long-standing expertise in reagent development and validation. Anti-GPCR antibody specificity has been a persistent challenge in the field — one with

GPCRs are no longer simple on/off switches. Discover how biased signaling and functional assays are reshaping GPCR drug discovery.

Modern drug discovery produces thousands of compounds—but only pharmacology turns assay signals into predictions. Explore the drug discovery pharmacology principles guiding receptor signaling, potency interpretation, residence time, and real-world drug behavior.

The A₂A adenosine receptor NanoBRET® competitive binding assay enables real-time quantification of ligand–receptor interactions in living cells. By combining NanoLuc-tagged receptors with fluorescent tracers, this approach allows direct measurement of binding displacement, delivering robust pIC₅₀ and pKᵢ values that align with established pharmacology. In this article, we examine the assay principle, validation strategy, and performance across reference antagonists and agonis

The 5th GPCRs-Targeted Drug Discovery Summit is coming to Boston — and DrGPCR will be there. Here's what's on the agenda, who's presenting, and how to register with an exclusive discount.

Quantifying receptor selectivity requires cancelling cell effects, using full curves, and separating bias from subtype preference. Learn the correct framework.

👉 Ambition is the default setting of biotech. Platforms expand. Indications multiply. New opportunities appear constantly. That is not a flaw. It is the nature of scientific possibility. 👉 The problem begins when ambition grows faster than structure. What feels like momentum can quietly become dilution. More programs. Broader roadmaps. Increasing complexity. And slowly, strategic focus weakens . This is the hidden cost of ambition in biotech leadership. Not failure. Not poo

The first GPCR Pharmacology AMA of 2026 takes place February 26 at 1 PM EST. Join Terry’s Corner to discuss receptor theory, biased signaling, and mechanistic interpretation in drug discovery.

👉 In early-stage biotech, activity often feels like strategy. The platform is advancing, multiple indications are progressing, a grant application is underway, and early partnership conversations are taking shape. At the same time, the team is preparing for biotech fundraising. On the surface, this looks like a strength. There is movement across the board. Each initiative has logic behind it. Each program appears to increase optionality and reduce risk. 👉 This is where str

GPCRs are one of the most important families of therapeutic targets in the pharmaceutical industry. They are involved in several pathologies, ranging from neurological, oncological, degenerative, metabolic, immunological… around a third of the drugs in clinical use are GPCR ligands

Integrated GPCR drug discovery demands more than isolated experiments. It requires alignment across chemistry, modeling, pharmacology, and translational strategy. This week, we introduce the newly structured Dr. GPCR University — ten reformatted masterclasses now fully integrated into Premium — and what that means for discovery teams.

Dr. GPCR and Eurofins DiscoverX announce a strategic partnership to accelerate GPCR drug discovery by expanding access to validated, industry-standard cell-based assay platforms supporting pharmacological characterization, screening, and regulatory-compliant development.

Drug discovery does not move in fixed conclusions. As datasets expand and systems are tested under new conditions, interpretations often require adjustment. What initially appears mechanistically clear can become more nuanced when additional experiments are layered in.

👉 Most biotech founders  do not realize they are in trouble when the money runs out. By then, the situation is already decided. 👉 The real issue begins earlier, at a point where the company is still operating, the science is progressing, and milestones are being met. On paper, things look fine. In reality, something more subtle starts to shift. 👉 Decision-making changes. Plans that once felt flexible start to feel constrained. Conversations move from options to assumption

The Dr. GPCR University has undergone a structural redesign. This is a focused soft launch—prioritizing usability, clarity, and strategic navigation. You can now search courses by level, topic, or instructor. Each course page includes a short trailer, defined learning outcomes, and explicit take-home messages. Full course videos stream directly from the platform, and downloadable resources are available in one place.

👉 Strong biotech startups do not fail because the science is weak or the team is incapable. They fail when the pressure of fundraising slowly starts reshaping how decisions are made , long before anyone notices that strategy has begun to drift. In early-stage biotech, fundraising rarely feels like a strategic threat. It feels like a necessary distraction. Founders tell themselves that certain compromises are temporary, that clarity will return after the round closes. 👉 What

In early-stage drug discovery, one miscalculated liability can bring an otherwise promising scaffold to a complete halt. Rushing past early safety signals, especially those emerging from cytotoxicity or off-target activities, risks catastrophic consequences for both patient safety and project resources.